Page 1065 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

12 References

337. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for candidemia in patients without neutropenia. Candidemia Study
the selection of anti-infective agents for complicated intra- Group and the National Institute. N Engl J Med. November 17,
abdominal infections. Clin Infect Dis. 2003;37(8):997-1005. 1994;331(20):1325-1330.
338. Weinstein MP. Comparative evaluation of penicillin, ampicillin, 354. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of
and imipenem MICs and susceptibility breakpoints for van- invasive candidal infections: results of a prospective, random-
comycin-susceptible and vancomycin-resistant Enterococcus ized, multicenter study of fluconazole versus amphotericin B
faecalis and Enterococcus faecium. J Clin Microbiol. and review of the literature. Clin Infect Dis. 1996;23(5):964-972.
2001;39(7):2729-2731. 355. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and
339. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Increased sus- blinded multicenter trial of high-dose fluconazole plus placebo
ceptibility to vancomycin-resistant Enterococcus intesti- versus fluconazole plus amphotericin B as therapy for candi-
nal colonization persists after completion of anti-anaerobic demia and its consequences in nonneutropenic subjects. Clin
antibiotic treatment in mice. Infect Control Hosp Epidemiol. Infect Dis. 2003;36(10):1221-1228.
2004;25(5):373-379. 356. Bow EJ. Considerations in the approach to invasive fungal
340. Lee I, Barton TD. Viral respiratory tract infections in transplant infection in patients with haematological malignancies. Br J
patients: epidemiology, recognition and management. Drugs. Haematol. 2008;140(2):133-152.
2007;67(10):1411-1427. 357. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA.
341. Boeckh M. The challenge of respiratory virus infections Assessment of antifungal activities of fluconazole and amphoter-
in hematopoietic cell transplant recipients. Br J Haematol. icin B administered alone and in combination against Candida
November 2008;143(4):455-467. albicans by using a dynamic in vitro mycotic infection model.
342. Kim YJ, Boeckh M, Englund JA. Community respiratory virus Antimicrobial Agents Chemother. June 1998;42(6):1382-1386.
infections in immunocompromised patients: hematopoietic 358. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller
stem cell and solid organ transplant recipients, and individuals MA. Antifungal pharmacodynamic characteristics of fluco-
with human immunodeficiency virus infection. Semin Respir nazole and amphotericin B tested against Candida albicans.
Crit Care Med. April 2007;28(2):222-242. Antimicrobial Agents Chemother. June 1997;41(6):1392-1395.
343. Ljungman P. Respiratory virus infections in stem cell trans- 359. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus
plant patients: the European experience. Biol Blood Marrow a regimen of amphotericin B followed by fluconazole for
Transplant. 2001;7(suppl):5S-7S. candidaemia in non-neutropenic patients: a randomised non-
344. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe inferiority trial. Lancet. 2005;366(9495):1435-1442.
disease in patients with 2009 pandemic influenza (H1N1) virus 360. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal
infection. CMAJ. February 23, 2010;182(3):257-264. drugs in fungal infections: a comparison. Drugs. January 1,
345. Segal BH, Bow EJ, Menichetti F. Fungal infections in nontrans- 2011;71(1):11-41.
plant patients with hematologic malignancies. Infect Dis Clin 361. Denning DW. Echinocandin antifungal drugs. Lancet.
North Am. 2002;16(4):935-964, vii. 2003;362(9390):1142-1151.
346. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current 362. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin
problems in treatment of invasive fungal infections in neutrope- versus liposomal amphotericin B for candidaemia and invasive
nic patients. Infect Dis Clin North Am. 1996;10(2):365-400. candidosis: a phase III randomised double-blind trial. Lancet.
347. Crislip MA, Edwards JE Jr. Candidiasis. Infect Dis Clin North 2007;369(9572):1519-1527.
Am. 1989;3(1):103-133. 363. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin ver-
348. Mermel LA, Allon M, Bouza E, et al. Clinical practice guide- sus fluconazole for invasive candidiasis. New Engl J Med.
lines for the diagnosis and management of intravascular 2007;356(24):2472-2482.
catheter-related infection: 2009 Update by the Infectious Diseases 364. Scheven M, Schwegler F. Antagonistic interactions between
Society of America. Clin Infect Dis. July 1, 2009;49(1):1-45. azoles and amphotericin B with yeasts depend on azole lipo-
349. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice philia for special test conditions in vitro. Antimicrob Agents
guidelines for the management of candidiasis: 2009 update Chemother. 1995;39(8):1779-1783.
by the Infectious Diseases Society of America. Clin Infect Dis. 365. Steinbach WJ, Stevens DA, Denning DW. Combination and
March 1, 2009;48(5):503-535. sequential antifungal therapy for invasive aspergillosis: review
350. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspo- of published in vitro and in vivo interactions and 6281 clini-
fungin and amphotericin B for invasive candidiasis. N Engl J cal cases from 1966 to 2001. Clin Infect Dis. 2003;37(suppl
Med. 2002;347(25):2020-2029. 3):S188-S224.
351. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study 366. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis
comparing fluconazole with amphotericin B/5-flucytosine for after itraconazole: evidence for significant antagonism. Mycoses.
the treatment of systemic Candida infections in intensive care 1993;36:421-424.
patients. Infection. 1996;24(6):426-432. 367. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and out-
352. Phillips P, Shafran S, Garber G, et al. Multicenter randomized comes of candidemia in 2019 patients: data from the prospec-
trial of fluconazole versus amphotericin B for treatment of can- tive antifungal therapy alliance registry. Clin Infect Dis. June 15,
didemia in non-neutropenic patients. Canadian Candidemia 2009;48(12):1695-1703.
Study Group. Eur J Clin Microbiol Infect Dis. 1997;16(5):337-345. 368. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of
353. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial com- Candidemia: emergence of non- Candida albicans species and
paring fluconazole with amphotericin B for the treatment of antifungal resistance. Am J Med. 1996;100:617-623.

Section05-O-ref.indd 12 1/20/2015 4:51:20 PM